Mektovi (Binemetinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Mektovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in combination with Braftovi (Encorafenib). Mektovi is also referred to by its drug name, Binemetinib.

Mektovi is a member of the class of drugs called kinase inhibitors. Mektovi is believed to work by blocking the action of a protein that signals lung cancer cells to divide and grow.

How do I take it?
Prescribing information states that Mektovi is taken orally as a tablet twice daily, with or without food.

Mektovi should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Mektovi lists common side effects including fatigue, nausea, diarrhea, muscle and joint pain, vomiting, abdominal pain, vision problems, constipation, trouble breathing, rash, and cough. 

Rare but serious side effects listed for Mektovi include new cancers, heart problems, blood clots, eye problems, interstitial lung disease, liver problems, severe bleeding, and fetal harm.

For more details about this treatment, visit:

Label: Mektovi — Binimetinib Tablet, Film Coated — DailyMed 

Binimetinib — MedlinePlus

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in